Aristocrat Technology has gone “too far” in seeking full profits from the sale of Konami Australia’s infringing pokie machines, with Konami arguing the court should calculate damages in relation to what proportion of its machines were created using components that infringe the gaming giant’s patent.
Gaming giant Aristocrat Technologies Australia can look over the tax returns of rival Konami Australia as the two companies prepare for next week’s hearing over how much Konami should pay in damages for patent infringement.
A court has barred US drug company Merck Sharp & Dohme from denying that an agreement made with German pharmaceutical company Merck KGaA was governed by German law, settling a key question before a trade mark case between the two drug giants goes to trial.
A developer of what’s now being called the “Infamous Mod” for video game Grand Theft Auto, which gives players extra powers, is confident he can defend the copyright case brought against him by Take-Two Interactive and its subsidiary Rockstar Games.
A senior Piper Alderman partner who has launched a sex discrimination case against the law firm rejected “reasonable settlement offers” that would have allowed her to leave the partnership on a “dignified basis”, counsel for the firm has told a court.
In a win for the corporate watchdog, a court has found collapsed education provider Vocation engaged in misleading and deceptive conduct and breached its continuous disclosure obligations by failing to inform shareholders of problems with a large government contract.
A judge has found a senior female partner at Piper Alderman has not provided sufficient evidence that the firm moved to oust her from its ranks because she is a woman, in a ruling dismissing her bid for an order halting the firm from moving forward with a meeting on the proposed expulsion.
The job of a senior Piper Alderman partner is in jeopardy after a court refused to extend an injunction preventing her from being ousted from the partnership while she battles a sex discrimination case against the firm.
A judge has denied Mylan’s bid to temporarily block Sun Pharma and Cipla from making generic versions of anti-cholesterol drug Lipidil while it appeals a ruling invalidating several claims of its patents for the drug, citing the “difficulty, complexity and uncertainty” in assessing compensation under an undertaking as to damages in pharmaceutical patent proceedings.
Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.